Lokivetmab Biosimilar Canine Monoclonal Antibody (IL-31) for Research
Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs.[1] It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-319-1mg | 1mg | 618 |
| GMP-Bios-ab-319-10mg | 10mg | |
| GMP-Bios-ab-319-100mg | 100mg | |
| GMP-Bios-ab-319-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lokivetmab biosimilar, Canine Whole Mab: Anti-IL31 therapeutic antibody |
| INN Name | Lokivetmab |
| Target | IL31 |
| Format | Canine Whole mAb |
| Derivation | Caninized |
| Species Reactivity | Canine |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Zoetis |
| Conditions Approved | Canine atopic dermatitis |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - IL31
1. Protein Interleukin-31
2. Gene IL31
3. Organism Homo sapiens (Human)
Function
Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:15184896).
May function in skin immunity (PubMed:15184896).
Enhances myeloid progenitor cell survival in vitro (By similarity).
Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity).

